IP Library › Granted Patent US 10,006,030
Granted Patent B2
US 10,006,030 · App. 15/326,044 · Granted Jun 26, 2018

RNA interference compositions targeting heat shock protein 90 and methods of use thereof

Inventors: Amotz Shemi (Herzliya, IL); Elina Zorde Khvalevsky (Jerusalem, IL)
Assignee: SILENSEED LTD.
C12N15/1135A61K9/0024A61K31/713A61K47/26A61K47/34C12N2310/14C12N2310/344C12N2310/351C12N2320/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,006,030
App. No.
15/326,044
Granted
Jun 26, 2018
Kind
B2
Abstract

This disclosure relates to RNA interference (RNAi) compositions that target expression of heat shock protein 90 (HSP90) in a subject. Polymeric delivery devices for providing the RNAi compositions are also described, as are methods of treating cancer using the described RNAi compositions.

Claims (6)

1. An RNAi (RNA interference) agent for treating a patient having a cancer in which cells of the cancer are expressing heat shock protein 90 (HSP90), the RNAi agent comprising a double-stranded RNA molecule that targets a HSP90 sequence set forth as SEQ ID NO: 1, or a double-stranded RNA molecule that targets a HSP90 sequence set forth as SEQ ID NO: 2, wherein the RNAi agent that targets SEQ ID NO: 1 comprises a sense strand of SEQ ID NO: 4 and an antisense strand of SEQ ID NO: 8, and wherein the RNAi agent that targets SEQ ID NO: 2 comprises a sense strand of SEQ ID NO: 5 and an antisense strand of SEQ ID NO: 9.

2. The RNAi agent of claim 1 , wherein at least one of the sense and antisense strands is modified by at least one modification selected from the group consisting of 2′-O-methyl, 2′-O-(2-methoxyethyl), 2′-F, locked nucleic acid (LNA), and phosphorothioate.

3. The RNAi agent of claim 2 , wherein the sense strand of the RNAi agent that targets SEQ ID NO: 1 is 2′-O-methyl-modified, and comprises SEQ ID NO: 7.

4. The RNAi agent of claim 1 , wherein the RNAi agent is conjugated to a cholesterol, α-tocopherol moiety, or a cell penetrating peptide.

5. A method for treating a cancer expressing HSP90 in a subject, comprising:

administering the RNAi agent of claim 1 to the subject, thereby treating the cancer.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2017
From: SHEMI, AMOTZ; ZORDE KHVALEVSKY, ELINA
To: SILENSEED LTD.
Reel/Frame 040985/0029 →
Continuity (2)
Provisional Application 62023982 · Jul 14, 2014
Related Publication 20170283803A1 · Oct 5, 2017